BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionCreative Planning
Latest Disclosed Ownership119,661 shares
Latest Disclosed Value $ 8,886,011
Creative Planning reports 8.15% increase in ownership of BBIO / BridgeBio Pharma, Inc.

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 119,661 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $8,886,026 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 110,643 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 8.15% during the quarter. The current value of the position is $7,835,402 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 119,661 9,018 8.15 8,886 5.00 0.0059
2026-02-17 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 110,643 16,787 17.89 8,463 73.64 0.0061
2025-11-14 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 93,856 18,568 24.66 4,875 49.97 0.0037
2025-08-08 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 75,288 13,924 22.69 3,251 53.23 0.0028
2025-05-15 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 61,364 17,433 39.68 2,121 76.02 0.0020
2025-02-14 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 43,931 12,667 40.52 1,205 56.09 0.0012
2024-10-11 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 31,264 31,264 772 0.0008
2024-05-13 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 0 -5,033 -100.00 0 -100.00
2024-02-14 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 5,033 5,033 203 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.